Growth in ophthalmology no longer starts in the operating room - it starts with the patient experience.

In this episode of Peer2Peer: The Podcast, host Dr Ben LaHood is joined by Dr Erik Mertens and Amanda Cardwell Carones to explore how deliberately designing the patient journey can transform patient satisfaction, strengthen trust and build a thriving, future-ready practice.

In this episode, we cover:

This episode is essential listening for ophthalmologists, cataract surgeons, clinic owners and healthcare leaders looking to connect clinical excellence with business success - without losing sight of what matters most: the patient.

Hear our AI-powered Deep Dive into the first peer-reviewed paper on the RayOne Galaxy spiral IOL.

This revolutionary non-diffractive lens was designed with AI, and the clinical results are speaking for themselves. We cut through the jargon and deliver the key findings in a fast, 15-minute discussion you can't afford to miss. In this 15-minute breakdown, you will learn:

- Why patients rate halo and glare levels with Galaxy as 'very low'.

- The sweet spot of functional vision: a smooth defocus curve spanning from +1.00 D to –2.80 D.

- The role of AI-assisted design in perfecting the optic before it ever entered an eye.

- The core data: Excellent monocular and binocular visual acuity across all tested distances.

Read the full paper for more information: https://journals.healio.com/doi/epdf/10.3928/1081597X-20250829-01

This podcast was created with the assistance of artificial intelligence. While every effort has been made to ensure accuracy, listeners are encouraged to refer to the original publication for complete details.

In this episode of Peer2Peer by Rayner, host Dr Ben LaHood (Australia) is joined by Mr Allon Barsam (UK) and Dr Deb Ristvedt (USA) to discuss the exciting news that RayOne EMV Toric has received FDA approval.

Together, they explore:

The clinical pathway and IDE study behind FDA approval.

How RayOne EMV Toric’s global success shaped its journey to the US market.

Surgical pearls and insights from experienced international users.

Why this milestone represents a new era for astigmatism correction in cataract surgery.

With RayOne EMV and EMV Toric lenses implanted worldwide in 75+ countries, this episode highlights how proven performance and surgeon trust have paved the way for US approval.

Dr Paul Singh and Dr Kendall Donaldson come together at the AECOS 2025 to explore the evolving role of OMIDRIA in cataract surgery. As the only FDA-approved intracameral NSAID, OMIDRIA continues to deliver meaningful clinical benefit - reducing inflammation, preventing complications, and improving patient outcomes - while easing or removing the burden of post-op drop regimens.

Listeners will hear real-world insights from the Bascom study and clinical practice, including how OMIDRIA-based dropless protocols can streamline workflow, enhance staff efficiency, improve patient satisfaction, and reduce costs. Importantly, OMIDRIA now maintains separate payment status in both Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) for 100% of fee-for-service Medicare patients.*

*OMIDRIA qualifies for separate payment across both ASC and HOPD settings as it fulfils the requirements established in the non-opioid as a surgical supply provision by CMS. 

Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA videos and podcasts are for the attention of US HCPs only. Please rely on your clinical judgment when considering treatment approaches. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of August 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants.

US-OM-2500051 07/25

Dr Ben LaHood sits down with Dr Erik Mertens and Dr Dick Vuijk from Medipolis Eye Centre in Antwerp, Belgium to discuss their transition from traditional phaco machines to the more intuitive Sophi system. They share the immediate changes they noticed in the OR and how Sophi has since become central to their cataract procedures.

The conversation highlights how Sophi brings a modern approach to cataract surgery - with streamlined setup, smoother workflows, refined phaco performance, and a cleaner, more efficient environment. Beyond technology, the surgeons also reflect on its impact on surgical teams, patient experience, cost, sustainability, and mobile surgery setups.

Whether you’re considering a trial or exploring a full switch, this episode offers first-hand insights and practical takeaways from surgeons who have made the change.

Discover Sophi: rayner.com/sophi

Curious about what Rayner has planned for ESCRS this year – after last year’s ground-breaking launch of the first-ever AI-designed spiral IOL?

In this special episode, Chief Marketing Officer Chris Willis is joined by Nathalie Martin, European Marketing Manager, and Anne Nestor, Medical Communications Manager, as they pull back the curtain on Rayner’s plans for ESCRS 2025 in Copenhagen – promising their most interactive and immersive congress yet.

Get the inside scoop on Rayner’s innovations: the revolutionary Galaxy IOL, hands-on comparisons with trifocal lenses using the RALV vision simulator, high-tech wetlabs featuring expert demos on the super-efficient Sophi phaco machine, and the debut of EyeJourney, a digital app transforming the patient experience.

Packed with exclusive insights and behind-the-scenes stories, this episode is your front-row pass to everything Rayner has in store – and will have you making their booth (C2.041) your must-visit stop in Copenhagen!

What if the true measure of success in cataract surgery isn’t just clinical results, but how patients themselves feel after treatment? In this episode, host Dr Ben LaHood sits down with leading experts Mr Sheraz Daya and Miss Pei Fen Lin to uncover how Patient Reported Outcome Measures (PROMs) are changing the game. From cutting-edge digital tools like RayPRO, and a shift toward value-based care, they reveal how listening to patients is transforming ophthalmology from the inside out. Whether you’re a clinician or simply curious about the future of healthcare, this conversation will challenge how you think about care and outcomes.

Dr Ben LaHood is joined by Professor Michael Amon - the inventor of the Sulcoflex supplementary IOL - and refractive specialist, Dr Michael Rossiter Thornton to explore the role of the Sulcoflex lens in managing unexpected refractive outcomes. The discussion highlights real-world surgical experiences, strategies for addressing refractive surprises, and how the Sulcoflex lens offers a valuable secondary solution for enhancing visual results post-cataract or refractive lens surgery.

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.

© 2025 Rayner Group, all rights reserved. Rayner and Sulcoflex are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

At the Ophthalpreneurs 2025 meeting in Italy, Dr Ben LaHood (Australia) hosted a discussion with ophthalmologists Mr Kieren Darcy (UK) and Dr Andrzej Dmitriew (Poland) about the evolving landscape of premium IOLs and the transition from diffractive to refractive technology with the introduction of RayOne Galaxy, the world’s first spiral IOL. The conversation delved into the impact of bothersome dysphotopsia on patient satisfaction and how the RayOne Galaxy lens addresses common issues like halos and glare whilst delivering full range of vision. The surgeons also shared real-world experiences with the lens, including cases involving family members and a Masterchef celebrity, along with the outcomes they’ve observed. Dr Dmitriew further discussed his role as a Rayner Centre of Excellence and how integrating the Sophi Phaco System has the potential to enhance surgical outcomes in his practice.

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.

© 2025 Rayner Group, all rights reserved. Rayner, RayOne and Galaxy are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Join the study Principal Investigators, Paul Singh, Cathy McCabe, and Brian Shafer, as they discuss preliminary findings from their recent study looking at a dropless postoperative surgery regimen including OMIDRIA vs. a standard topical regimen. Discover how using OMIDRIA as part of a dropless regimen can streamline surgical processes, enhance patient compliance, and reduce the burden of topical drops. Learn how this approach not only improves patient outcomes and satisfaction but also increases operational efficiency within clinics by minimizing the time spent on post-operative eye drop management. Learn why now is the ideal time to incorporate a dropless strategy. You’ll hear the compelling initial data, including information addressing common concerns about patient compliance and inflammation control.

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease. Please use clinical judgment when considering treatment. Refer to Rayner product labeling and instructions for use. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of March 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants. Rayner®, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA podcasts are for the attention of US HCPs only. US-OM-2500001 03/25